RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models

AIDS Research and Therapy

Volumn 6, Issue , 2009, Pages

  Jiang, Yonghou ^a   Tian, Baoping ^a   Saifuddin, Mohammed ^b   Agy, Michael B ^a   Emau, Peter ^a   Cairns, J Scott ^c   Tsai, Che Chung ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c Fifth Opus Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; MEDROXYPROGESTERONE ACETATE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLERIXAFOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS ANTIBODY; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CHIMERA; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INCIDENCE; MACACA NEMESTRINA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS EXPRESSING HUMAN IMMUNODEFICIENCY VIRUS 1 REVERSE TRANSCRIPTASE; SINGLE DRUG DOSE; VAGINITIS; VIREMIA; VIRUS DETECTION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 77952963008     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-6-23     Document Type: Article

References (46)

1. Cohen MS, Gay C, Kashuba ADM, Blower S, Paxton L. Narrative Review: Antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007, 146:591-601.
2. Klasse PJ, Shattock R, Moore JP. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Ann Rev Med 2008, 59:455-471. 10.1146/annurev.med.59.061206.112737, 17892435.
3. Lederman MM, Offord RE, Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nature Review Immunology 2006, 6:371-382.
4. Stone A, Jiang S. Microbicides: stopping HIV at the gate. Lancet 2006, 368:431-433. 10.1016/S0140-6736(06)69131-9, 16890813.
5. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003, 1:25-34. 10.1038/nrmicro729, 15040177.
6. Trager RS. Microbicides: Raising New Barriers HIV Infection. Science 2003, 299:39. 10.1126/science.299.5603.39, 12511630.
7. Turpin JA. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin Investig Drugs 2002, 11:1077-1097. 10.1517/13543784.11.8.1077, 12150703.
8. Moench TR, Chipato T, Nancy S, Padian NS. Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices. AIDS 2001, 15:1595-1602. 10.1097/00002030-200109070-00001, 11546933.
9. McCormack S, Hayes R, Lacey CJ, Johnson AM. Science, medicine, and the future: Microbicides in HIV prevention. BMJ 2001, 322:410-413. 1119634, 11179162, 10.1136/bmj.322.7283.410.
10. Pauwels R, DeClercq E. Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:211-221.
11. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ, Springer MS, Moore JP. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005, 438:99-102. 10.1038/nature04055, 16258536.
12. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, Piatak M, Lifson JD, Salkowitz JR, Rodriguez B, Blauvelt A, Hartley O. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004, 306:485-487. 10.1126/science.1099288, 15486300.
13. Tsai C-C, Emau P, Jiang YH, Agy MB, Shattock RJ, Schmidt A, Morton WR, Gustafson KR, Boyd MR. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 2004, 20:11-18. 10.1089/088922204322749459, 15000694.
14. Jiang YH, Emau P, Cairns JS, Flanary L, Morton WR, McCarthy TD, Tsai C-C. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2005, 21:207-213. 10.1089/aid.2005.21.207, 15795526.
15. D'Cruz OJ, Uckun FM. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother 2006, 57:411-423. 10.1093/jac/dki464, 16431862.
16. Patton DL, Sweeney YT, Balkus JE, Rohan LC, Moncla BJ, Parniak MA, Hillier SL. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. Antimicrob Agents Chemother 2007, 51:1608-1615. 1855550, 17353240, 10.1128/AAC.00984-06.
17. Pani A, Musiu C, Loi AG, Mai A, Loddo R, La Colla P, Marongiu ME. DABOs as candidates to prevent mucosal HIV transmission. Antivir Chem Chemother 2001, 12:51-59.
18. Barnard J, Borkow G, Parniak MA. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 1997, 36:7786-7792. 10.1021/bi970140u, 9201921.
19. Balzarini J, Naesens L, Verbeken E, Laga M, Van Damme L, Parniak M, Van Mellaert L, Anne J, De Clercq E. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 1998, 12:1129-1138. 10.1097/00002030-199810000-00004, 9677161.
20. Zussman A, Lara L, Lara HH, Bentwich Z, Borkow G. Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS 2003, 17:653-661. 10.1097/00002030-200303280-00002, 12646787.
21. Fletcher P, Kiselyeva Y, Wallace G, Romano J, Griffin G, Margolis L, Shattock R. The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol 2005, 79:11179-11186. 1193640, 16103169, 10.1128/JVI.79.17.11179-11186.2005.
22. Van Herrewege Y, Michiels J, Van Roey J, Fransen K, Kestens L, Balzarini J, Lewi P, Vanham G, Janssen P. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004, 48:337-339. 310190, 14693562, 10.1128/AAC.48.1.337-339.2004.
23. Uberla K, Stahl-Hennig C, Bottiger D, Matz-Rensing K, Kaup FJ, Li J, Haseltine WA, Fleckenstein B, Hunsmann G, Oberg B, Joseph S. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci USA 1995, 2:8210-8214.
24. Balzarini J, DeClercq E, Uberla K. SIV/HIV-1 hybrid virus expressing the reverse transcriptase gene of HIV-1 remains sensitive to HIV-1 specific reverse transcriptase inhibitors after passage in rhesus macaques. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15:1-4.
25. Zuber B, Bottiger D, Benthin R, ten Haaft P, Heeney J, Wahren B, Oberg B. An in vivo model for HIV resistance development. AIDS Res Hum Retroviruses 2001, 17:631-635. 10.1089/088922201300119734, 11375059.
26. Ambrose Z, Boltz V, Palmer S, Coffin JM, Hughes SH, Kewalramani VN. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J Virol 2004, 78:13553-13561. 533891, 15564466, 10.1128/JVI.78.24.13553-13561.2004.
27. Akiyama H, Ido E, Akahata W, Kuwata T, Miura T, Hayami M. Construction and in vivo infection of a new simian/human immunodeficiency virus chimera containing the reverse transcriptase gene and the 3' half of the genomic region of human immunodeficiency virus type 1. J Gen Virol 2003, 84:1663-1669. 10.1099/vir.0.18843-0, 12810859.
28. Soderberg K, Denekamp L, Nikiforow S, Sautter K, Desrosiers RC, Alexander LA. Nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. J Virol 2002, 76:5803-5806. 137045, 11992009, 10.1128/JVI.76.11.5803-5806.2002.
29. Ambrose Z, Palmer S, Boltz VF, Kearney M, Larsen K, Polacino P, Flanary L, Oswald K, Piatak M, Smedley J, Shao W, Bischofberger N, Maldarelli F, Kimata JT, Mellors JW, Hu SL, Coffin JM, Lifson JD, Kewalramani VN. Suppression of Viremia and Evolution of HIV-1 Drug Resistance in a Macaque Model for Antiretroviral Therapy. J Virol 2007, 81:12145-12155. 2169021, 17855539, 10.1128/JVI.01301-07.
30. Mori K, Yasutomi Y, Sawada S, Villinger F, Sugama K, Rosenwith B, Heeney JL, Uberla K, Yamazaki S, Ansari AA, Rubsamen-Waigmann H. Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. J Virol 2000, 74:5747-5753. 112067, 10846052, 10.1128/JVI.74.13.5747-5753.2000.
31. North TW, Van Rompay KK, Higgins J, Matthews TB, Wadford DA, Pedersen NC, Schinazi RF. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J Virol 2005, 79:7349-7354. 1143671, 15919889, 10.1128/JVI.79.12.7349-7354.2005.
32. Hofman MJ, Higgins J, Matthews TB, Pedersen NC, Tan C, Schinazi RF, North TW. Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004, 48:3483-3490. 514752, 15328115, 10.1128/AAC.48.9.3483-3490.2004.
33. Rosenwirth B, ten Haaft P, Bogers WM, Nieuwenhuis IG, Niphuis H, Kuhn EM, Bischofberger N, Heeney JL, Uberla K. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques. J Virol 2000, 74:1704-1711. 111645, 10644340, 10.1128/JVI.74.4.1704-1711.2000.
34. Turville SG, Aravantinou M, Miller T, Kenney J, Teitelbaum A, Hu L, Chudolij A, Zydowsky TM, Piatak M, Bess JW, Lifson JD, Blanchard J, Gettie A, Robbiani M. Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS ONE 2008, 3:1-14.
35. Pal R, Nuttall J, Galmin L, Weiss D, Chung HK, Romano J. Characterization of vaginal transmission of a simian human immunodeficiency virus (SHIV) encoding the reverse transcriptase gene from HIV-1 in Chinese rhesus macaques. Virology 2009, 386:102-108. 10.1016/j.virol.2009.01.002, 19195672.
36. Jiang Y, Tian B, Agy MB, Saifuddin M, Tsai C-C. Macaca fascicularis are highly susceptible to an RT-SHIV following intravaginal inoculation: a new model for microbicide evaluation. J Med Primatol 2009, 38(Suppl.1):39-46. 10.1111/j.1600-0684.2009.00374.x.
37. Marx PA, Spira AI, Gettie A, Dailey PJ, Veazey RS, Lackner AA, Mahoney CJ, Miller CJ, Claypool LE, Ho DD, Alexander NJ. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996, 2:1084-1089. 10.1038/nm1096-1084, 8837605.
38. Trunova N, Tsai L, Tung S, Schneider E, Harouse J, Gettie A, Simon V, Blanchard J, Cheng-Mayer C. Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. Virology 2006, 352:169-177. 10.1016/j.virol.2006.04.004, 16730772.
39. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, Moore JP. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000, 97:5639-5644. 25881, 10779565, 10.1073/pnas.090576697.
40. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, Bridger G, Henson GW. Pharmacokinetics and safety of AMD- a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 3100, 44:1667-1673.
41. Klasse PJ, Rosenkilde MM, Signoret N, Pelchen-Matthews A, Schwartz TW, Marsh M. CD4-Chemokine Receptor Hybrids in Human Immunodeficiency Virus Type 1 Infection. J Virol 1999, 73:7453-7466. 104272, 10438835.
42. Tsai L, Trunova N, Gettie A, Mohri H, Bohm R, Saifuddin M, Cheng-Mayer C. Efficient repeated low-dose intravaginal infection with X4 and R5 SHIVs in rhesus macaque: implications for HIV-1 transmission in humans. Virology 2007, 362:207-216. 1941575, 17258783, 10.1016/j.virol.2006.12.024.
43. Reimann KA, Li JT, Veazey R, Halloran M, Park IW, Karlsson GB, Sodroski J, Letvin NL. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996, 70:6922-6928. 190741, 8794335.
44. Emau P, Tian B, O"keefe BR, Mori T, MacMahon JB, Palmer KE, Jiang Y, Bekele G, Tsai CC. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J Med Primatol 2007, 36:244-253. 10.1111/j.1600-0684.2007.00242.x, 17669213.
45. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63. 10.1016/0022-1759(83)90303-4, 6606682.
46. Watson A, Ranchalis J, Travis B, McClure J, Sutton W, Johnson PR, Hu SL, Haigwood NL. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol 1997, 71:284-290. 191049, 8985348.